Alzheimer's and Dementia

This segment focuses on what it means to be involved in the Lewy body dementia shape trial. Dr. Daniel Burdick, a physician's investigator at Evergreen Hospital Medical Center in Kirkland, Washington walks Suzanne Newman through the process. Participating in a clinical trial is a donation of time to the global effort to develop better treatments for Parkinson's disease and Dementia with Lewy Bodies. It can be involved. This particular trial is a 6-8 month process with 9 or 10 visits to the Kirkland site, one every 4-6 weeks, each one a couple to several hours each, with doctors spending lots of time with them. Doctors ask detailed questions and get to know their experiences in much greater detail, and people have said that it's a positive experience because they feel really connected. A research coordinator becomes their navigator through the trial.

Dr. Daniel Burdick from the Evergreen Hospital Medical Center in Kirkland, Washington, joins Suzanne to talk about Lewy body dementia. It encompasses two separate disorders: Parkinson's dementia and Dementia with Lewy Bodies, which are very similar. One of the best ways to make your future better, if you have dementia, if you want to be proactive with the disease, is to volunteer in a clinical trial.

Learn about the different types of Alzheimer's research studies, what's involved in participating, and how you can get involved. Suzanne Newman joins Dr. Cherian Verghese, Principal Researcher at the forefront of Alzheimer's disease at Keystone Clinical Studies LLC in the Philadelphia area. When we face cancer or heart disease, we think our bodies are failing. When it comes to something in our minds, we think we are failing, as something personal, but our mind sits within our brain, and these are illnesses, just like cancer or COVID. In the old days, there was a sense of learned helplessness — I can't do anything about it, so why bother? — but that's not the case any more.

Learn about the types of Alzheimer's research studies and what's involved in participating. Suzanne Newman joins Dr. Cherian Verghese, Principal Researcher at the forefront of Alzheimer's disease at Keystone Clinical Studies LLC in the Philadelphia area. In the phase of informed consent, participants and trial partners are appraised on details about the medicine, that it’s voluntary, outlines potential side effects, not charged to insurance, that participants can withdraw at any time, and that they can also talk to the ethics committee at any time. A trial partner spends time with the participant, a family member, friend, or neighbor — conducting the study needs someone who can tell us about how the participant functions at home with their activities of daily living.

This segment continues the conversation about how Alzheimer's disease progresses. Suzanne Newman joins Dr. Cherian Verghese to talk about a special program for those who are in the beginning or medium stages of Alzheimer's disease. Dr. Verghese is Principal Researcher at Keystone Clinical Studies LLC in the Philadelphia area. In earlier stages, people can be helped at home with assisted living, with family support. Going into moderate or severe dementia, we'd need in-home care and at some stages institutional care. It's physically demanding to help someone with their activities of daily living. Sadly, African Americans are twice as likely, and Latinos about one and a half times as likely, than in Caucasians. They are disproportionately affected, but participation was lower in trials, making it hard to extrapolate drug trial results.

Suzanne Newman joins Dr. Cherian Verghese to talk about a special program for those who are in the beginning or medium stages of Alzheimer's disease. Dr. Verghese is Principal Researcher at Keystone Clinical Studies LLC in the Philadelphia area. His mother died from Alzheimer's disease five years ago, and it transformed his efforts as a physician-investigator. Keystone is almost entirely focused on Alzheimer's. This segment concerns the differences between dementia and Alzheimer's, and how the disease progresses. The prevalence of Alzheimer's dementia is 5% in people 65 years old. By the age of 80, it's 40% or more.

In this segment, Alzheimer's disease and dementia expert Dr. Danielle Goldfarb talks about clinical trials. Dr. Goldfarb is a neurologist and psychiatrist, as well as a physician researcher at Banner Sun Health Research Center in Sun Sun City, Arizona. Clinical trials are the cutting edge of new treatments and breakthroughs. In this segment Dr. Goldfarb talks about some of the promising latest news in clinical trials.

In this segment, Alzheimer's disease and dementia expert Dr. Danielle Goldfarb talks about clinical trials. Dr. Goldfarb is a neurologist and psychiatrist, as well as a physician researcher at Banner Sun Health Research Center in Sun Sun City, Arizona. Clinical trials in an option for some patients, and it’s beneficial to participate. Dr. Goldfarb talks about what happens when you're considering taking part to help determine whether a newly-developed drug is safe, well-tolerated and effective.

This hour with Dementia expert Faith Marshall of Awakenings Hypnosis & Coaching deals with how to communicate with loved ones facing Alzheimer's and dementia....

This hour with Dementia expert Faith Marshall of Awakenings Hypnosis & Coaching deals with how to communicate with loved ones facing Alzheimer's and dementia....